Currently, standard first-line chemotherapy with or without immunotherapy for patients with non-small-cell lung cancer (NSCLC) with HER2 mutations has limited efficacy.
Wiktoria Bogdanska, PharmD, BCOP
Advertisement
Articles by Wiktoria Bogdanska, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Five-Year NATALEE Data Show Ribociclib Improves Outcomes in High-Risk HR+/HER2– Early Breast Cancer
2
Abemaciclib Provides Long-Term Survival Benefit in High-Risk Early Breast Cancer
3
Operationalizing Epcoritamab-GemOx in Practice: A Focus on EPCORE NHL-2
4
Durvalumab Plus Chemotherapy Sets New Standard in Resectable Gastric and GEJ Cancer
5
